...
首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >DNA fusion vaccine designs to induce tumor-lytic CD8+ T-cell attack via the immunodominant cysteine-containing epitope of NY-ESO 1
【24h】

DNA fusion vaccine designs to induce tumor-lytic CD8+ T-cell attack via the immunodominant cysteine-containing epitope of NY-ESO 1

机译:DNA融合疫苗设计通过NY-ESO 1的具有免疫优势的含半胱氨酸表位来诱导肿瘤溶解CD8 + T细胞攻击

获取原文
获取原文并翻译 | 示例

摘要

The cancer/testis antigen NY-ESO-1 contains an immunodominant HLA-A2-binding peptide (SLLMWITQC), designated S9C, an attractive target for vaccination against several human cancers. As cysteine contains a reactive -SH, the oxidation status of exogenous synthetic peptide is uncertain. We have designed tolerance-breaking DNA fusion vaccines incorporating a domain of tetanus toxin fused to tumor-derived peptide sequences (p.DOM-peptide), placed at the C-terminus for optimal immunogenicity. In a "humanized" HLA-A2 preclinical model, p.DOM-S9C primed S9C-specific CD8+ T cells more effectively than adjuvanted synthetic peptide. A DNA vaccine encoding the full NY-ESO-1 sequence alone induced only weak S9C-specific responses, amplified by addition of DOM sequence. The analog peptide (SLLMWITQL) also primed peptide-specific CD8+ T cells, again increased by DNA delivery. Importantly, T cells induced by S9C-encoding DNA vaccines killed tumor cells expressing endogenous NY-ESO-1. Only a fraction of T cells induced by the S9L-encoding DNA vaccines was able to recognize S9C and kill tumor cells. These data indicate that DNA vaccines mimic posttranslational modifications of -SH-containing peptides expressed by tumor cells. Instability of synthetic peptides and the potential dangers of analog peptides contrast with the ability of DNA vaccines to induce high levels of tumor-lytic peptide-specific CD8+ T cells. These findings encourage clinical exploration of this vaccine strategy to target NY-ESO-1. What's new? Vaccine-targeted cancer peptides containing amino acids such as cysteine, can be post-translationally modified in unpredictable ways by tumor cells, making peptide design difficult. In contrast, DNA fusion gene vaccines deliver peptide in a form which mimics tumor cell processing and induce high levels of tumor-lytic CD8+ T cells. This simple strategy obviates the need for analogue peptides, which, even when optimized, generate both relevant and irrelevant responses.
机译:癌症/睾丸抗原NY-ESO-1包含一种免疫显性HLA-A2结合肽(SLLMWITQC),命名为S9C,是针对几种人类癌症进行疫苗接种的诱人靶标。由于半胱氨酸含有反应性-SH,因此外源合成肽的氧化状态尚不确定。我们设计了结合了破伤风毒素域与肿瘤衍生肽序列(p.DOM-肽)融合的破伤风DNA融合疫苗,将其置于C末端以获得最佳免疫原性。在“人源化” HLA-A2临床前模型中,p.DOM-S9C比佐剂合成肽更有效地引发了S9C特异性CD8 + T细胞。单独编码完整NY-ESO-1序列的DNA疫苗仅诱导弱的S9C特异性反应,并通过添加DOM序列进行扩增。类似物肽(SLLMWITQL)也引发了肽特异性CD8 + T细胞,再次由于DNA传递而增加。重要的是,由编码S9C的DNA疫苗诱导的T细胞杀死了表达内源性NY-ESO-1的肿瘤细胞。由编码S9L的DNA疫苗诱导的T细胞中只有一小部分能够识别S9C并杀死肿瘤细胞。这些数据表明DNA疫苗模拟了肿瘤细胞表达的含-SH的肽的翻译后修饰。合成肽的不稳定性和类似物肽的潜在危险与DNA疫苗诱导高水平的溶瘤肽特异性CD8 + T细胞的能力形成对比。这些发现鼓励对该疫苗策略靶向NY-ESO-1的临床探索。什么是新的?含有氨基酸(例如半胱氨酸)的疫苗靶向癌肽可以被肿瘤细胞以不可预测的方式进行翻译后修饰,从而使肽设计变得困难。相反,DNA融合基因疫苗以模拟肿瘤细胞加工并诱导高水平的肿瘤溶解CD8 + T细胞形式输送肽。这种简单的策略消除了对类似肽的需求,即使经过优化,类似肽也会产生相关和不相关的反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号